Photosensitive pro-drug nanoassemblies harboring a chemotherapeutic dormancy function potentiates cancer immunotherapy

Jianjun Cheng,Haitian Zhao,Bin Li,Hua Zhang,Qianyu Zhao,Shiyao Fu,Ying Han,Weihong Lu,Jiahua Shi,Xin Yang

DOI: https://doi.org/10.1016/j.apsb.2022.06.008

IF: 14.903

2023-01-01

Acta Pharmaceutica Sinica B

Abstract:Immunotherapy combined with effective therapeutics such as chemotherapy and photody-namic therapy have been shown to be a successful strategy to activate anti-tumor immune responses for improved anticancer treatment. However, developing multifunctional biodegradable, biocompatible, low-toxic but highly efficient, and clinically available transformed nano-immunostimulants remains a challenge and is in great demand. Herein, we report and design of a novel carrier-free photo -chemother-apeutic nano-prodrug COS-BA/Ce 6 NPs by combining three multifunctional componentsda self -assembled natural small molecule betulinic acid (BA), a water-soluble chitosan oligosaccharide (COS), and a low toxic photosensitizer chlorin e6 (Ce6)dto augment the antitumor efficacy of the im-mune adjuvant anti-PD-L1-mediated cancer immunotherapy. We show that the designed nanodrugs harbored a smart and distinctive "dormancy" characteristic in chemotherapeutic effect with desired lower cytotoxicity, and multiple favorable therapeutic features including improved 1O2 generation induced by the reduced energy gap of Ce6, pH-responsiveness, good biodegradability, and biocompatibility, ensuring a highly efficient, synergistic photochemotherapy. Moreover, when combined with anti-PD-L1 therapy, both nano-coassembly based chemotherapy and chemotherapy/photodynamic therapy (PDT) could effec-tively activate antitumor immunity when treating primary or distant tumors, opening up potentially attrac-tive possibilities for clinical immunotherapy. 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).